Stories

In his latest article for Forbes, Guadalupe Hayes-Mota, director, bioethics shows how building an ethical business from day one can be a strategic advantage that attracts partners, talent and investors who care about long-term impact.

Every decision—from which disease to target to how data is used—has moral implications. Yet ethics is too often treated as a compliance box to check rather than a source of innovation and trust. Building an ethical business from day one can be a strategic advantage that attracts partners, talent and investors who care about long-term impact.

Guadalupe Hayes-Mota, director, bioethics, published by Forbes.